Basilea publishes investor presentation on anti-infectives strategy, pipeline and hospital brands Cresemba, Zevtera
Reuters2026/08/05 05:45- Basilea highlighted a partnership-led, asset-light anti-infectives model built around hospital brands Cresemba and Zevtera.
- Cresemba marketed in 76 countries; moving annual total sales of USD 782 million for April 2025 to March 2026, up 27% year-on-year.
- Zevtera U.S. launch in July 2025 via Innoviva Specialty Therapeutics; U.S. market exclusivity runs until April 2034.
- Phase 3 pipeline centered on fosmanogepix in invasive candidiasis and invasive mold infections, supported by expanded-access use in 500+ patients.
- Ceftibuten-ledaborbactam positioned as an oral option for resistant Gram-negative cUTI; Phase 3 initiation targeted for early 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI computing power demand ignites nuclear capital enthusiasm: Holtec (HNUC.US) plans IPO to raise 900 million dollars, targeting a 10 billion dollar valuation.
Nuclear supplier Holtec is seeking to raise up to $900 million through a U.S. initial public offering, as companies aim to profit from the growing electricity demand driven by data centers.
Longest in Five Years! US Stock Earnings Upward Revision Trend Hits Record Since 2021, May Signal Another Profitable Earnings Season Ahead
Supported by strong corporate earnings prospects, U.S. stocks are demonstrating considerable resilience and are withstanding the impact of rising inflationary pressures.
Middle East Turmoil, Higher Crude Bills Damp European Bourses Midday
Phoenix Metals Gets Amended Exploration Permit for Greenwood Project
Crypto prices
More
